BioSpace News Archive

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s Desert Oasis Healthcare system.

OliX Pharmaceuticals, Inc. today announced that the first patient has been successfully dosed in a Phase 1 clinical trial ( NCT05643118 ), evaluating OLX10212, an investigational RNAi therapeutic intended for the treatment of age-related macular degeneration (AMD), including geographic atrophy (GA) and neovascular (nv) AMD.

Delcath Systems, Inc. announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit.

ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual Guggenheim Healthcare Talks.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration will hold an Advisory Committee Meeting to discuss the company’s Biologics License Application for NurOwn® for the treatment of amyotrophic lateral sclerosis.

Trevena, Inc. today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, prior to the market open on Thursday, March 30, 2023.

Tonix Pharmaceuticals Holding Corp. today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical and Farooq Nasar, Ph.D., Senior Principal Investigator, both of Tonix Pharmaceuticals, will deliver oral presentations at the World Vaccine Congress, which will be held in Washington D.C., April 3 - 6, 2023.

Venus Concept Inc. announced financial results for the three and twelve months ended December 31, 2022.

Tango Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

ArriVent Biopharma, Inc. today announced the completion of a $155 million oversubscribed Series B financing.